“Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis”, J of Skin, vol. 6, no. 6, p. s74, Nov. 2022, doi: 10.25251/skin.6.supp.74.